Clinical Trials Logo

Alzheimer Disease, Late Onset clinical trials

View clinical trials related to Alzheimer Disease, Late Onset.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT06078891 Enrolling by invitation - Clinical trials for Alzheimer Disease, Late Onset

Does BCG Vaccination Reduce Biomarkers of Alzheimer's Disease?

BCG-AD
Start date: July 1, 2023
Phase: Early Phase 1
Study type: Interventional

The goal of this clinical trial is to test whether vaccination with the BCG vaccine may improve the blood level of a biomarker of Alzheimer's disease (AD) in participants who are cognitively- and functionally- intact elderly (70-80 years old) participants, who display pathologically high levels of the blood biomarker. The main questions it aims to answer are: - Does BCG vaccination lower the plasma level of phosphorylated Tau protein (p-tau181). - Do vaccinated participants remains stable cognitively. Participants will be asked to: - Undergo cognitive and behavioral evaluation. - Receive 3 BCG vaccinations over the course of 1 year. - Perform blood tests on several occasions. All participants will be treated and followed.